We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.
The current GLYC market cap is 16.68M. The company's latest EPS is USD -0.5722 and P/E is -0.45.
| Quarter End | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Revenue | 0 | 10k | 0 | 0 | 0 |
| Operating Income | -9.73M | -9.59M | -11.12M | -10.36M | -11.23M |
| Net Income | -9.2M | -9.08M | -10.74M | -10.1M | -9.82M |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Revenue | 0 | 10.16M | 1.16M | 75k | 10k |
| Operating Income | -61.39M | -51.51M | -63.45M | -47.4M | -39.28M |
| Net Income | -57.89M | -51.03M | -63.43M | -46.69M | -36.9M |
| Quarter End | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Assets | 53.2M | 45.32M | 34.21M | 24.42M | 15.7M |
| Total Liabilities | 6.65M | 6.9M | 5.29M | 4.36M | 4.32M |
| Total Equity | 46.55M | 38.41M | 28.91M | 20.06M | 11.38M |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Assets | 167.97M | 142.83M | 94.35M | 51.81M | 45.32M |
| Total Liabilities | 13.77M | 14.61M | 12.74M | 8.88M | 6.9M |
| Total Equity | 154.2M | 128.22M | 81.6M | 42.93M | 38.41M |
| Quarter End | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Operating | -27.27M | -34.88M | -10.51M | -19.4M | -27.4M |
| Investing | -21k | -21k | -7k | -10k | -10k |
| Financing | 28.82M | 28.82M | 5k | 5k | 5k |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Operating | -51.98M | -39.24M | -57.49M | -46.46M | -34.88M |
| Investing | -145k | -68k | -15k | -84k | -21k |
| Financing | 412k | 18.14M | 10.72M | 4.16M | 28.82M |
| Market Cap | 16.68M |
| Price to Earnings Ratio | -0.45 |
| Price to Sales Ratio | 1.3k |
| Price to Cash Ratio | 0.4 |
| Price to Book Ratio | 0.44 |
| Dividend Yield | - |
| Shares Outstanding | 64.48M |
| Average Volume (1 week) | 516.49k |
| Average Volume (1 Month) | 660.8k |
| 52 Week Change | -91.38% |
| 52 Week High | 3.5299 |
| 52 Week Low | 0.1406 |
| Spread (Intraday) | 0.01 (4.77%) |
| Company Name | GlycoMimetics Inc |
| Address |
1209 orange street wilmington, delaware 19801 |
| Website | https://www.glycomimetics.com |
| Industry | pharmaceutical preparations (2834) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
